Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp (NASDAQ: WGS) drives innovation in genomic medicine through advanced sequencing technologies and clinical decision support tools. This news hub provides investors and healthcare professionals with essential updates on the company's progress in transforming rare disease diagnosis and precision medicine.
Access authoritative reports covering earnings announcements, research collaborations, regulatory milestones, and technology advancements. Our curated collection includes press releases about clinical study validations, healthcare system partnerships, and innovations in rapid whole genome sequencing applications.
Stay informed about developments in pediatric genetics, oncology diagnostics, and data integration initiatives that demonstrate GeneDx's leadership in translating genomic insights into actionable health solutions. Regular updates ensure you never miss critical information about diagnostic capabilities expansion or strategic growth in the genomic testing market.
Bookmark this page for direct access to verified updates and analysis-free reporting on WGS's role in advancing evidence-based genetic medicine. Check back frequently to monitor how GeneDx continues to shape the future of personalized healthcare through cutting-edge science and clinical partnerships.
GeneDx (WGS) has announced plans to acquire Fabric Genomics, an AI-powered genomic interpretation pioneer, in a deal worth up to $51 million. The acquisition combines GeneDx's extensive rare disease data asset with Fabric Genomics' AI platform to enable decentralized testing with centralized intelligence.
The transaction, expected to close in Q2 2025, includes $33 million in cash upon closing, with additional $18 million tied to milestone achievements. This strategic move will expand GeneDx's addressable market through multiple revenue streams:
- NICU Genomic Testing: Targeting the underserved market where less than 5% of 400,000 annual NICU admissions receive genetic testing
- Genomic Newborn Screening: Addressing a market of 3.7M U.S. births and 130M globally
- Global Commercial Expansion: Enabling local sequencing with centralized AI interpretation
- Platform Economics: Leveraging 750,000+ exomes/genomes dataset for AI development and clinical decision support
GeneDx (Nasdaq: WGS), a genomic insights company, has scheduled the release of its first quarter 2025 financial results before market opening on Wednesday, April 30, 2025. The company's management will hold a conference call at 8:30 a.m. Eastern Time on the same day to discuss the quarterly financial and operating results. Interested investors must register online to participate in the conference call. Both live and archived versions of the event will be accessible through the 'Events' section on GeneDx's investor relations website.
GeneDx (WGS) has announced a commercial expansion into Inborn Errors of Immunity (IEI), targeting nearly 500 genetic disorders affecting over 200,000 patients in the US. The company aims to improve patient outcomes through exome and genome testing solutions for inherited immunological conditions.
The expansion highlights the superiority of genomic sequencing over panel-based testing, with IEI diagnostic yields of approximately 40% compared to 29% from multi-gene panels. This approach enables faster accurate diagnoses and personalized treatment decisions, including bone marrow transplantation, gene therapy, and other therapies available for over 50% of IEI patients.
In the past 18 months, GeneDx has sequenced more than 5,000 IEI patients. The company's dataset includes over 750,000 clinical exomes and genomes enriched with IEI data, opening opportunities for biopharma partnerships in research and therapeutic development.
GeneDx (WGS), a genomic insights company, has announced the granting of 46,340 restricted stock units (RSUs) to ten newly-hired employees as employment inducement awards. The grants, effective March 15, 2025, were approved by the compensation committee under GeneDx's 2023 Equity Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest equally over a four-year period, contingent on continued employment. Each RSU represents the right to receive one share of GeneDx's Class A Common Stock upon settlement. The company specializes in rare disease diagnostics, offering exome and genome tests to enable personalized healthcare solutions.
GeneDx (WGS) has been named one of Fast Company's World's Most Innovative Companies of 2025, ranking No. 2 in the Biotech category. The company is recognized for revolutionizing whole genome sequencing (WGS) with turnaround times as fast as 48 hours.
The company is leading innovation in genomic newborn screening (gNBS) through their GUARDIAN study, the largest of its kind examining gNBS in diverse newborn populations. GeneDx's screening capabilities now cover over 450 actionable genetic conditions that traditional newborn screening methods typically miss.
With 25 years of experience, GeneDx focuses on delivering early genetic disease diagnosis and improving healthcare outcomes through genomic insights. Their approach aims to transform healthcare delivery by identifying conditions before symptoms appear, potentially reducing healthcare system burden and improving patient outcomes.
GeneDx (WGS) announced its upcoming presentations at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Meeting, showcasing its genomic research and innovation through three platform presentations and two poster presentations.
The company will present its AI-powered gene ranker Multiscore, which prioritizes genes with positive findings in exome and genome sequences by analyzing patient clinical data. This tool aims to accelerate analysis, reduce turnaround times, and lower costs for patients.
Additionally, GeneDx will present findings from an RNA sequencing program for variant of uncertain significance (VUS) resolution, and showcase collaborations with PacBio, GUARDIAN, and Seqfirst. The research presentations include studies on HiFi sequencing applications, expanded newborn screening, and parental needs during pediatric whole genome sequencing.
GeneDx (WGS) has unveiled Multiscore, an advanced AI-powered decision support tool integrated into their genetic interpretation platform. The tool aims to revolutionize genetic analysis by improving diagnostic efficiency and streamlining workflows.
Multiscore leverages GeneDx's proprietary dataset of 750,000 clinical exome and genome sequences and over six million phenotypic datapoints, combined with publicly available data. The AI tool prioritizes genes in exome and genome sequences by ranking them based on patient clinical presentation, enabling faster and more accurate identification of genetic conditions.
The technology will be presented at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting. By incorporating phenotypic similarities into gene ranking criteria, the tool helps identify pathogenic diagnoses even in complex cases where symptoms may not match textbook descriptions, ultimately reducing manual review time and accelerating result delivery.
GeneDx (Nasdaq: WGS) has expanded its genetic testing services to include cerebral palsy (CP) as a new indication during Cerebral Palsy Awareness Month. The company's research shows that approximately 300 genes are associated with CP, with genetic conditions identified as the underlying cause in nearly 1 in 3 CP patients.
The expansion aims to improve access to exome and genome testing for CP patients, which affects approximately 10,000 children annually. Recent data published by GeneDx in JAMA demonstrated a more than 30% diagnostic rate in a cohort of over 1,300 CP patients.
The company's testing can help guide personalized treatment strategies, identify eligibility for targeted therapies, and connect patients with advocacy groups. GeneDx has also established a collaboration with Geisinger to create a large-scale harmonized dataset for gene discovery and additional research in CP.
GeneDx (Nasdaq: WGS) announced the publication of the Seqfirst-neo study results in the American Journal of Human Genetics, conducted with Seattle Children's and the University of Washington. The study introduces a new approach using exclusion criteria for rapid genome sequencing (rGS) in NICU settings, demonstrating that at least 60% of level IV NICU infants should receive rGS.
Key findings from the 408-infant study showed that 49.2% of infants in the interventional group received a precise genetic diagnosis (PrGD), compared to 9.7% in conventional care. The study revealed that 42% of diagnosed infants would have been missed using conventional protocols, with 69% being non-white. The new approach led to clinical management changes in nearly 97% of diagnosed cases.
GeneDx also announced the launch of ultraRapid Whole Genome Sequencing, offering results in as soon as 48 hours for NICU and PICU patients, and integration with Epic Aura to streamline genetic diagnoses delivery.
GeneDx (WGS) has announced the launch of ultraRapid Whole Genome Sequencing, delivering genomic insights for NICU and PICU patients in as fast as 48 hours. This accelerated testing addresses the critical underutilization of genetic testing in NICUs, where up to 25% of patients likely have genetic disorders, yet less than 5% undergo testing.
The service, available for ordering in March through the GeneDx portal and Epic Aura integration, can lead to healthcare savings exceeding $15,000 per child by reducing unnecessary treatments and shortening NICU stays. Without genetic diagnosis, NICU stays are typically 15-20 days longer. The company's advanced technology and experience in sequencing over 750,000 exomes and genomes enables efficient testing at scale.
Genetic diseases are the leading identifiable cause of infant death, and genetic diagnosis can impact clinical management for more than 60% of critically ill infants.
